[1]
|
Tilg, H., Adolph, T.E., Dudek, M., et al. (2021) Non-Alcoholic Fatty Liver Disease: The Interplay between Metabolism, Microbes and Immunity. Nature Metabolism, 3, 1596-1607. https://doi.org/10.1038/s42255-021-00501-9
|
[2]
|
Henao-Mejia, J., Elinav, E., Jin, C., et al. (2012) Inflammasome-Mediated Dysbiosis Regulates Progression of NAFLD and Obesity. Nature, 482, 179-185. https://doi.org/10.1038/nature10809
|
[3]
|
Tilg, H. and Effenberger, M. (2020) From NAFLD to MAFLD: When Pathophysiology Succeeds. Nature Reviews Gastroenterology & Hepatology, 17, 387-388. https://doi.org/10.1038/s41575-020-0316-6
|
[4]
|
Wang, X., Zheng, Z., Caviglia, J.M., et al. (2016) Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 24, 848-862. https://doi.org/10.1016/j.cmet.2016.09.016
|
[5]
|
Mahlapuu, M., Caputo, M., Xia, Y., et al. (2022) GCKIII Kinases in Lipotoxicity: Roles in NAFLD and Beyond. Hepatology Communications, 6, 2613-2622. https://doi.org/10.1002/hep4.2013
|
[6]
|
Herman, M.A. and Samuel, V.T. (2016) The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis. Trends in Endocrinology & Metabolism, 27, 719-730. https://doi.org/10.1016/j.tem.2016.06.005
|
[7]
|
Porto, A., Pan, Z., Zhou, W., et al. (2022) Macronutrient and Micronutrient Intake in Adolescents with Non-Alcoholic Fatty Liver Disease: The Association with Disease Severity. Journal of Pediatric Gastroenterology and Nutrition, 75, 666-674. https://doi.org/10.1097/MPG.0000000000003578
|
[8]
|
De Munck, T., Xu, P., Verwijs, H., et al. (2020) Intestinal Permeability in Human Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Liver International, 40, 2906-2916. https://doi.org/10.1111/liv.14696
|
[9]
|
Fang, J., Yu, C.H., Li, X.J., et al. (2022) Gut Dysbiosis in Nonalcoholic Fatty Liver Disease: Pathogenesis, Diagnosis, and Therapeutic Implications. Frontiers in Cellular and Infection Microbiology, 12, Article 997018. https://doi.org/10.3389/fcimb.2022.997018
|
[10]
|
Cai, D., Yuan, M., Frantz, D.F., et al. (2005) Local and Systemic Insulin Resistance Resulting from Hepatic Activation of IKK-Beta and NF-KappaB. Nature Medicine, 11, 183-190. https://doi.org/10.1038/nm1166
|
[11]
|
Huh, J.Y. and Saltiel, A.R. (2021) Roles of IκB Kinases and TANK-Binding Kinase 1 in Hepatic Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Experimental & Molecular Medicine, 53, 1697-1705. https://doi.org/10.1038/s12276-021-00712-w
|
[12]
|
Duan, Y., Pan, X., Luo, J., et al. (2022) Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 13, Article 880298. https://doi.org/10.3389/fimmu.2022.880298
|
[13]
|
Risi, R., Tozzi, R. and Watanabe, M. (2021) Beyond Weight Loss in Nonalcoholic Fatty Liver Disease: The Role of Carbohydrate Restriction. Current Opinion in Clinical Nutrition & Metabolic Care, 24, 349-353. https://doi.org/10.1097/MCO.0000000000000762
|
[14]
|
Wong, V.W., Wong, G.L., Chan, R.S., et al. (2018) Beneficial Effects of Lifestyle Intervention in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 69, 1349-1356. https://doi.org/10.1016/j.jhep.2018.08.011
|
[15]
|
Estes, C., Anstee, Q.M., Arias-Loste, M.T., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. https://doi.org/10.1016/j.jhep.2018.05.036
|
[16]
|
Ali, A., Amin, M.J., Ahmed, M.U., et al. (2022) Frequency of Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Associated Risk Factors among Type-2 Diabetics. Pakistan Journal of Medical Sciences, 38, 28-33. https://doi.org/10.12669/pjms.38.1.4968
|
[17]
|
Petit, J.M. and Vergès, B. (2017) Glp-1 Receptor Agonists in NAFLD. Diabetes & Metabolism, 43, 2S28-2S33. https://doi.org/10.1016/S1262-3636(17)30070-8
|
[18]
|
Colosimo, S., Ravaioli, F., Petroni, M.L., et al. (2021) Effects of Antidiabetic Agents on Steatosis and Fibrosis Biomarkers in Type 2 Diabetes: A Real-World Data Analysis. Liver International, 41, 731-742. https://doi.org/10.1111/liv.14799
|
[19]
|
Zhang, Q.Q. and Lu, L.G. (2015) Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. Journal of Clinical and Translational Hepatology, 3, 78-84. https://doi.org/10.14218/JCTH.2014.00037
|
[20]
|
Van Der Graaff, D., Chotkoe, S., De Winter, B., et al. (2021) Vasoconstrictor Antagonism Improves Functional and Structural Vascular Alterations and Liver Damage in Rats with Early NAFLD. JHEP Reports, 4, Article 100412. https://doi.org/10.1016/j.jhepr.2021.100412
|
[21]
|
Nadinskaia, M., Maevskaya, M., Ivashkin, V., et al. (2021) Ursodeoxycholic Acid as a Means of Preventing Atherosclerosis, Steatosis and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. World Journal of Gastroenterology, 27, 959-975. https://doi.org/10.3748/wjg.v27.i10.959
|
[22]
|
Aron-Wisnewsky, J., Warmbrunn, M.V., Nieuwdorp, M., et al. (2020) Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology, 158, 1881-1898. https://pubmed.ncbi.nlm.nih.gov/32044317/ https://doi.org/10.1053/j.gastro.2020.01.049
|
[23]
|
Siddiqui, M.S., Idowu, M.O., Parmar, D., et al. (2021) A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 19, 2670-2672. https://doi.org/10.1016/j.cgh.2020.10.051
|
[24]
|
Harrison, S.A., Bashir, M.R., Guy, C.D., et al. (2019) Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet, 394, 2012-2024. https://doi.org/10.1016/S0140-6736(19)32517-6
|
[25]
|
Talukdar, S. and Kharitonenkov, A. (2021) FGF19 and FGF21: In NASH We Trust. Molecular Metabolism, 46, Article 101152. https://doi.org/10.1016/j.molmet.2020.101152
|
[26]
|
Harrison, S.A., Neff, G., Guy, C.D., et al. (2021) Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis. Gastroenterology, 160, 219-231. https://doi.org/10.1053/j.gastro.2020.08.004
|
[27]
|
Safadi, R., Braun, M., Francis, A., et al. (2021) Randomised Clinical Trial: A Phase 2 Double-Blind Study of Namodenoson in Non-Alcoholic Fatty Liver Disease and Steatohepatitis. Alimentary Pharmacology & Therapeutics, 54, 1405-1415. https://doi.org/10.1111/apt.16664
|